New biomarkers for diagnosis and prognosis of localized prostate cancer

2018 ◽  
Vol 52 ◽  
pp. 9-16 ◽  
Author(s):  
Dimitry A. Chistiakov ◽  
Veronika A. Myasoedova ◽  
Andrey V. Grechko ◽  
Alexandra A. Melnichenko ◽  
Alexander N. Orekhov
Keyword(s):  
Prostate Cancer ◽  
Localized Prostate Cancer ◽  
Diagnosis And Prognosis ◽  
New Biomarkers

scholarly journals The Role of miR-107 in Prostate Cancer: A Review and Experimental Evidence

2021 ◽  
Author(s):  
Maria Elizbeth Alvarez-Sanchez ◽  
Oscar Rojas Espinosa ◽  
Julio César Torres-Romero ◽  
Ereth Ameyatzin Robles Chávez ◽  
Edgar Estrella-Parra ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Experimental Evidence ◽  
Cancer Progression ◽  
Signaling Cascades ◽  
Potential Utility ◽  
Diagnosis And Prognosis ◽  
Endogenous Regulators ◽  
New Biomarkers

Over the past two decades, several research groups have focused on the functioning of microRNAs (miRNAs), because many of them function as positive or negative endogenous regulators of processes that alter during the development of cancer. Prostate cancer is the second most commonly occurring cancer in men. New biomarkers are needed to support the diagnosis of prostate cancer. Although it is necessary to deepen the research on this molecule to explore its potential utility in the diagnosis, follow-up, and prognosis of cancer, our results support a role of miR-107 in the signaling cascades that allow cancer progression, and as shown here, in the progression of Prostate Cancer (PCa). These findings strongly suggest that miR-107 may be a potential circulating biomarker for the diagnosis and prognosis of prostate cancer.

scholarly journals Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS

2015 ◽  
Vol 2015 ◽  
pp. 1-23 ◽  
Author(s):  
Cordelia Geisler ◽  
Nadine T. Gaisa ◽  
David Pfister ◽  
Susanne Fuessel ◽  
Glen Kristiansen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Western Blot ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Prostate Tissue ◽  
Biochemical Relapse ◽  
Prostate Cancer Diagnosis ◽  
2D Dige ◽  
Diagnosis And Prognosis ◽  
New Biomarkers

This study was designed to identify and validate potential new biomarkers for prostate cancer and to distinguish patients with and without biochemical relapse. Prostate tissue samples analyzed by 2D-DIGE (two-dimensional difference in gel electrophoresis) and mass spectrometry (MS) revealed downregulation of secernin-1 (P< 0.044) in prostate cancer, while vinculin showed significant upregulation (P< 0.001). Secernin-1 overexpression in prostate tissue was validated using Western blot and immunohistochemistry while vinculin expression was validated using immunohistochemistry. These findings indicate that secernin-1 and vinculin are potential new tissue biomarkers for prostate cancer diagnosis and prognosis, respectively. For validation, protein levels in urine were also examined by Western blot analysis. Urinary vinculin levels in prostate cancer patients were significantly higher than in urine from nontumor patients (P= 0.006). Using multiple reaction monitoring-MS (MRM-MS) analysis, prostatic acid phosphatase (PAP) showed significant higher levels in the urine of prostate cancer patients compared to controls (P= 0.012), while galectin-3 showed significant lower levels in the urine of prostate cancer patients with biochemical relapse, compared to those without relapse (P= 0.017). Three proteins were successfully differentiated between patients with and without prostate cancer and patients with and without relapse by using MRM. Thus, this technique shows promise for implementation as a noninvasive clinical diagnostic technique.

scholarly journals Diagnosis and Prognosis of Prostate Cancer from Circulating Matrix Metalloproteinases and Inhibitors

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
William Khalil El-Chaer ◽  
Clayton Franco Moraes ◽  
Otávio Toledo Nóbrega
Keyword(s):  
Prostate Cancer ◽  
Matrix Metalloproteinases ◽  
Specific Antigen ◽  
Poor Quality ◽  
Screening Tools ◽  
Diagnosis And Prognosis ◽  
Precise Diagnosis ◽  
New Biomarkers

Although prostate cancer (PCa) is the sixth most common type of neoplasm in the world and the second in prevalence among men (10% of all cases), there is shortage of studies focused on primary prevention of the disorder as well as little understanding on its pathophysiology. Currently, the PCa screening tools are the prostate specific antigen (PSA) dosage conjugated to rectal examination and confirmed by prostate biopsy. Despite the name, the PSA presents reduced specificity, being necessary the identification of new biomarkers that allow an earlier and more precise diagnosis and even better prognosis. Several studies have associated matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) to PCa tumorigenesis and metastasis. Most of the studies so far have been carried out by investigating in situ expression of the metalloproteinases, either by transcriptional measures or by immunohistochemistry with biopsy or postoperative tissue. Investigations in human plasma and serum are scarce, and a bibliographical search resulted in 17 studies which are presented and interpreted herein. This narrative review discusses their settings and findings along with aspects related to circulating metalloproteinases as potential biomarkers for diagnosis or prognosis of the prostatic malignancy, expressing the authors' reticent view on their applicability due to the poor quality of evidence available.

1141: A Randomized Controlled Trial Comparing External Beam Radiation and Cryoablation in Localized Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 376-377 ◽  
Author(s):  
Bryan J. Donnelly ◽  
John C. Saliken ◽  
Penny Brasher ◽  
Scott Ernst ◽  
Harold Lau ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Localized Prostate Cancer ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Randomized Controlled

140: Racial Differences in Clinical Progression Among Medicare Recipients after Treatment for Clinically Localized Prostate Cancer

2006 ◽  
Vol 175 (4S) ◽  
pp. 45-46
Author(s):  
Jacob H. Cohen ◽  
Victor J. Schoenbach ◽  
Jay S. Kaufman ◽  
James A. Talcott ◽  
Paul A. Godley
Keyword(s):  
Prostate Cancer ◽  
Racial Differences ◽  
Localized Prostate Cancer ◽  
Clinical Progression
Sign in / Sign up

Export Citation Format

Share Document